Alteon to Present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
20 April 2005 - 2:06AM
PR Newswire (US)
Alteon to Present at the Rodman & Renshaw Techvest 2nd Annual
Global Healthcare Conference - Presentation to be Webcast -
PARSIPPANY, N.J., April 19 /PRNewswire-FirstCall/ -- Alteon Inc.
(AMEX:ALT) announced today that Kenneth I. Moch, President and
Chief Executive Officer, will participate in the Rodman &
Renshaw Techvest 2nd Annual Global Healthcare Conference in Paris.
Mr. Moch is scheduled to present on Wednesday, May 4, 2005 at 3:30
pm (9:30 am, ET). The presentation will be webcast and accessible
at Alteon's website, http://www.alteon.com/ . Note to Conference
Attendees: Alteon has made time available for one-on- one meetings
at the conference. Please contact the one-on-one conference desk or
contact Susan Pietropaolo directly if you are interested in setting
up a meeting. About Alteon Alteon is developing several new classes
of drugs that have shown the potential to reverse or slow down
diseases of aging and complications of diabetes. These compounds
appear to have an impact on a fundamental pathological process
caused by the progressive formation of protein-glucose complexes
called Advanced Glycation End-products (A.G.E.s). The formation and
crosslinking of A.G.E.s lead to a loss of flexibility and function
in body tissues and organs and have been shown to be a causative
factor in many age- related diseases and diabetic complications.
Alteon has created a library of novel classes of compounds
targeting the A.G.E. pathway. Alteon's lead compound alagebrium
chloride (formerly ALT-711), the only A.G.E. Crosslink Breaker in
advanced human testing, has demonstrated safety and efficacy in
several Phase 2 trials and is being developed for systolic
hypertension, heart failure and erectile dysfunction. Approximately
1,300 patients have been involved in alagebrium's human clinical
trials to date, of whom approximately 1,000 have received active
compound. Clinical studies of alagebrium include the Phase 2b
systolic hypertension trial, SPECTRA (Systolic Pressure Efficacy
and Safety Trial of Alagebrium), the Phase 2a heart failure study,
PEDESTAL (Patients with Impaired Ejection Fraction and Diastolic
Dysfunction: Efficacy and Safety Trial of ALagebrium), the Phase 2a
EMERALD study (Evaluation of Alagebrium in Erectile Dysfunction in
Diabetic Males on PDE5 Inhibitors), as well as a fourth study
exploring mechanism of action in endothelial dysfunction. In
February 2005, Alteon voluntarily and temporarily suspended
enrollment of new patients into the Company's ongoing alagebrium
clinical studies pending receipt of additional pre-clinical data,
which are expected by mid-year 2005. The Company expects that
decisions regarding resumption of enrollment will be made at that
time. For more detailed information about alagebrium, please visit
the scientific publications section of the Alteon website,
http://www.alteon.com/ . Any statements contained in this press
release that relate to future plans, events or performance are
forward-looking statements that involve risks and uncertainties
including, but not limited to, those relating to technology and
product development (including the possibility that early clinical
trial results may not be predictive of results that will be
obtained in large-scale testing or that any clinical trials will
not demonstrate sufficient safety and efficacy to obtain requisite
approvals or will not result in marketable products), regulatory
approval processes, intellectual property rights and litigation,
competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange
Commission. The information contained in this press release is
accurate as of the date indicated. Actual results, events or
performance may differ materially. Alteon undertakes no obligation
to publicly release the result of any revision to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. DATASOURCE: Alteon Inc. CONTACT: Susan M.
Pietropaolo, Director, Corporate Communications & Investor
Relations of Alteon Inc., +1-201-818-5537 dir., Web site:
http://www.alteon.com/
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon , News Articles